Abstract 4450: Cisplatin intercalated zirconium phosphate nanoparticles are cytotoxic to MCF-7 breast cancer cells via apoptosis

• Published in: Cancer research (Chicago, Ill.) Vol. 71; no. 8_Supplement; p. 4450
• Main Authors: Gonzalez, Millie L., Ortiz, Mayra, Baez, Adriana
• Format: Journal Article
• Language: English
• Published: 15.04.2011
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2011-4450

Abstract Purpose: Nanoparticle-mediated drug delivery has great potential for anticancer therapy. The purpose of this study was to determine the effectiveness of zirconium phosphate (ZrP) nanoparticles as carrier of the cytotoxic drug cisplatin in MCF-7 breast cancer cells. Methods: Cytotoxicity of ZrP, ZrP:cisplatin, and cisplatin were studied using the MTT Assay. Cell cycle analyses and apoptosis were analyzed using flow cytometry technology. Results: ZrP nanoparticles were not cytotoxic to MCF-7 cells. However, cell viability was reduced to 70% when MCF-7 cells were grown with ZrP: cisplatin 100μM. Cisplatin was cytotoxic to MCF-7 cells with an IC50 of 10 μM. The cytotoxic effect of cisplatin: ZrP is mediated by induction of apoptosis. AnnexinV/PI treated MCF-7 cells showed the apoptotic events in cisplatin -induced apoptosis. ZrP nanoparticles alone did not cause apoptosis to MCF-7 cells or peripheral blood lymphocytes. Conclusion: ZrP nanoparticles can significantly reduce side effects associated to systemic toxicity of anticancer agents and more studies are warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4450. doi:10.1158/1538-7445.AM2011-4450